[go: up one dir, main page]

DE69839224D1 - Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide - Google Patents

Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide

Info

Publication number
DE69839224D1
DE69839224D1 DE69839224T DE69839224T DE69839224D1 DE 69839224 D1 DE69839224 D1 DE 69839224D1 DE 69839224 T DE69839224 T DE 69839224T DE 69839224 T DE69839224 T DE 69839224T DE 69839224 D1 DE69839224 D1 DE 69839224D1
Authority
DE
Germany
Prior art keywords
taxoids
pharmaceutical composition
composition containing
containing cyclodextrins
cyclodextrins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839224T
Other languages
English (en)
Other versions
DE69839224T2 (de
Inventor
Joseph M Geczy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal AG filed Critical Hexal AG
Application granted granted Critical
Publication of DE69839224D1 publication Critical patent/DE69839224D1/de
Publication of DE69839224T2 publication Critical patent/DE69839224T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69839224T 1997-11-10 1998-11-09 Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide Expired - Lifetime DE69839224T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9701945 1997-11-10
HU9701945A HUP9701945A3 (en) 1997-11-10 1997-11-10 Pharmaceutical composition for injection containing cyclodextrin and taxoids
PCT/HU1998/000097 WO1999024073A1 (en) 1997-11-10 1998-11-09 Pharmaceutical compositions containing cyclodextrins and taxoids

Publications (2)

Publication Number Publication Date
DE69839224D1 true DE69839224D1 (de) 2008-04-17
DE69839224T2 DE69839224T2 (de) 2009-04-16

Family

ID=89995733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839224T Expired - Lifetime DE69839224T2 (de) 1997-11-10 1998-11-09 Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide

Country Status (19)

Country Link
US (1) US7671042B2 (de)
EP (1) EP1059942B1 (de)
JP (1) JP3656550B2 (de)
KR (1) KR100607391B1 (de)
CN (1) CN1222321C (de)
AR (1) AR015482A1 (de)
AT (1) ATE387916T1 (de)
AU (1) AU742036B2 (de)
BR (1) BR9814015A (de)
CA (1) CA2309326C (de)
DE (1) DE69839224T2 (de)
EA (1) EA002776B1 (de)
HU (1) HUP9701945A3 (de)
IL (1) IL135990A0 (de)
NO (1) NO329382B1 (de)
NZ (1) NZ504098A (de)
PL (1) PL199652B1 (de)
WO (1) WO1999024073A1 (de)
ZA (1) ZA989779B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
WO2003015828A1 (en) * 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
CN100384865C (zh) * 2001-11-02 2008-04-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
JP2006500387A (ja) * 2002-08-15 2006-01-05 雲清 劉 固形ナノ医薬およびその調製方法
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101020059B (zh) * 2006-02-15 2011-01-05 中国科学院上海药物研究所 一种含多烯紫杉醇类物质的药物组合物及其制备方法
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
WO2007142440A1 (en) * 2006-06-02 2007-12-13 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same
KR100917810B1 (ko) * 2006-06-02 2009-09-18 에스케이케미칼주식회사 저장안정성이 우수한 파클리탁셀 함유 주사제 조성물
CN100486645C (zh) 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
CA2683712A1 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical compositions
AU2008269179A1 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without Tween 80
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
KR20120130740A (ko) * 2011-05-23 2012-12-03 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
US11406595B2 (en) * 2012-05-21 2022-08-09 University Of Maryland, College Park Highly stable colloid from aqueous solutions of small organic molecules
CN104870001B (zh) 2012-11-15 2019-01-18 赛博尔泰克股份公司 用作消炎或免疫抑制有效成分的飞燕草素络合物
HK1215392A1 (zh) 2012-12-11 2016-08-26 赛博尔泰克股份公司 用於对抗黑色素瘤细胞的飞燕草素
CN105823810A (zh) * 2016-01-04 2016-08-03 杭州电子科技大学 紫杉醇化疗效果检测装置及检测方法
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
US12414914B2 (en) 2018-07-25 2025-09-16 Bika Biotechnology (Guangzhou) Co., Ltd Docetaxel composition for injection and preparation method therefor
PE20241300A1 (es) * 2021-05-26 2024-06-24 Daewoong Pharmaceutical Co Ltd Nueva formulacion para inyeccion que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
CN115960834B (zh) * 2023-03-07 2023-06-09 浙江省肿瘤医院 一种pd-1/ptx联合pd-1耐药模型建立的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法と用途
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物,その製造法および用途
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
CA2163837C (en) * 1994-12-13 1999-07-20 Robert K. Perrone Crystalline paclitaxel hydrates
HUP0600533A2 (en) * 2001-11-30 2006-11-28 Bristol Myers Squibb Co Paclitaxel solvates

Also Published As

Publication number Publication date
CA2309326C (en) 2010-12-21
EP1059942B1 (de) 2008-03-05
US7671042B2 (en) 2010-03-02
HU9701945D0 (en) 1998-01-28
JP2001522816A (ja) 2001-11-20
NO20002165L (no) 2000-07-07
PL340505A1 (en) 2001-02-12
NO20002165D0 (no) 2000-04-27
EA002776B1 (ru) 2002-08-29
WO1999024073B1 (en) 1999-07-08
BR9814015A (pt) 2000-09-26
AU1253899A (en) 1999-05-31
CA2309326A1 (en) 1999-05-20
NZ504098A (en) 2003-06-30
KR20010031967A (ko) 2001-04-16
US20070087999A1 (en) 2007-04-19
WO1999024073A1 (en) 1999-05-20
PL199652B1 (pl) 2008-10-31
DE69839224T2 (de) 2009-04-16
KR100607391B1 (ko) 2006-08-02
AU742036B2 (en) 2001-12-13
EA200000494A1 (ru) 2000-10-30
IL135990A0 (en) 2001-05-20
HUP9701945A1 (hu) 1999-09-28
CN1281373A (zh) 2001-01-24
ATE387916T1 (de) 2008-03-15
CN1222321C (zh) 2005-10-12
EP1059942A2 (de) 2000-12-20
ZA989779B (en) 1999-04-28
AR015482A1 (es) 2001-05-02
NO329382B1 (no) 2010-10-04
HUP9701945A3 (en) 2000-04-28
JP3656550B2 (ja) 2005-06-08

Similar Documents

Publication Publication Date Title
ATE387916T1 (de) Pharmazeutische zusammensetzung enthaltend cyclodextrine und taxoide
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
NO995925D0 (no) Farmasöytiske sammensetninger omfattende cyklodekstriner
DE69719834D1 (de) Dentalwerkstoffe enthaltend Cyclodextrine und phenolische Verbindungen
DE60029115D1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE69833464D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
DE69940904D1 (de) Pharmazeutische zusammensetzung enthaltend epothilone
ATE422359T1 (de) Verbindungen und pharmazeutische zusammensetzungen mit appetitunterdrückender aktivität
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE69704612D1 (de) Dentalmasse und dental-produkt
ATE222751T1 (de) Pharmazeutische aerosolzusammensetzung
DE60023792D1 (de) Karmin und Karamel enthaltende selbstbräunende Zusammensetzung
DE60003874D1 (de) Resistmaterialien und Verbindungen
ATE207468T1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
ATE211132T1 (de) Aromatische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE69732649D1 (de) Heteroarylsulfonamidderivate und diese enthaltende pharmazeutische zubereitungen
DE69524592D1 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ATE204266T1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE243517T1 (de) Einschlusskomplexe von dehydroepiandrosteron und korrespondierende pharmazeutische zusammenstellungen
DE69415570D1 (de) Esculetin Derivate und pharmazeutische Zusammenstellung
ATE228839T1 (de) Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen
ATE295150T1 (de) Pharmazeutische zusammensetzungen
DE69610085D1 (de) Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition